Malaria Consortium is one of the world's leading non-profit organizations dedicated to comprehensive control of malaria and other communicable diseases in Africa and Southeast Asia. Malaria Consortium works with communities, government and non-government agencies, academic institutions, and local and international organizations, to ensure delivery of effective services, provide technical support for monitoring and evaluation of programmes and activities for evidence-based decision-making and strategic planning. The organization works to improve not only the health of individuals, but also the capacity of national health systems, which helps to relieve poverty and support improved economic prosperity.
The SARMAAN II Project, an acronym for Safety and Antimicrobial Resistance of Mass Administration of Azithromycin among Children 1-59 Months in Nigeria is a large-scale initiative aimed at evaluating the safety and impact of azithromycin mass drug administration (MDA) on antimicrobial resistance and child mortality. The project has both an intervention and a research component, which will be implemented across ten states in Nigeria: Sokoto, Kano, Katsina, Kebbi, Kaduna, Jigawa, Zamfara, Bauchi, Gombe and Adamawa. The research component will be led by the Nigeria Institute of Medical Research (NIMR) in collaboration with the Federal and State Ministries of Health, national agencies such as Nigeria Centre for Disease Control and Prevention (NCDC) and National Primary Health Care Development Agency (NPHCDA), and international partners, including the University of Washington, University of California San Francisco, and the Institute for Disease Modeling. This research component will focus on monitoring drug safety (Adverse Drug Reactions), antimicrobial resistance, and mortality trends.
The intervention component will however involve a bi-annual (every 6 months) mass administration of azithromycin to children aged 1–59 months and will be implemented by Malaria Consortium alongside other key partners, including Sightsavers, eHealth Africa, African Field Epidemiology Network (AFENET), Mission to Save the Helpless (MiTOSATH), Solina Centre for International Development and Research, World Health Organization (WHO), United Nations International Children's Emergency Fund (UNICEF), and regulatory bodies such as NHREC and NAFDAC. Malaria Consortium will be implementing directly in Kaduna, Kebbi, Jigawa, Gombe and Adamawa states, while providing oversight to AFENET and MiTOSATH to implement in Katsina, Zamfara, Yobe and Bauchi States.
The primary goal of SARMAAN II is to explore the potential of azithromycin in reducing under-five morbidity and mortality in Nigeria, where the under-five mortality rate (U5MR) currently stands at 105 deaths per 1,000 live births, and the infant mortality rate (IMR) at 60 deaths per 1,000 live births. By addressing the leading causes of child mortality including respiratory infections, diarrhoea diseases, pneumonia, and malaria, the project aims to contribute to significant reductions in morbidity and hospitalization rates. To achieve measurable impact, the consortium is committed to reaching at least 80% coverage of eligible children across all implementing states during the MDA rounds.
We are recruiting to fill the position below:
Job Title: LGA Field Assistant
Location: Adamawa
Employment Type: Full Time
Purpose of the assignment
Objective
Methodology
Engagement and Onboarding:
Embedded Support Model:
Support and Supervision:
Reporting:
Key Responsibilities
Deliverables
Required Specification for Consultant
Application Closing Date
31 March, 2026
How to Apply
Interested and qualified candidates should:
Click here to apply online
Note